ALK and non-small cell lung carcinoma: This study systematically combines data from published clinical trials to evaluate the efficacy and safety of crizotinib in the treatment of ALK-positive NSCLC using a random effect model following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines[17].